# Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy

> **NCT01437488** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 14 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Cabazitaxel
- **DRUG:** Neulasta
- **PROCEDURE:** CT Scan
- **BIOLOGICAL:** Blood Draw

## Key facts

- **NCT ID:** NCT01437488
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-16
- **Primary completion:** 2014-08-04
- **Final completion:** 2017-03-30
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01437488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01437488, "Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01437488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*